NCCN Quick Guide™ | Chronic Lymphocytic Leukemia

2 of 2 NCCN QUICK GUIDE tm Chronic Lymphocytic Leukemia, 2019 PAT-N-1140-0319 What are treatment options? CLL with del(17p) or TP53 mutation „„ For first-line treatment, a clinical trial may be an option. Ibrutinib is the preferred treatment if not in a clinical trial. 23 „„ For next-in-line treatment, ibrutinib, venetoclax with rituximab, duvelisib, and idelalisib with rituximab are preferred. 24 CLL without del(17p) and TP53 mutation „„ For first-line treatment, ibrutinib is the preferred treatment. Other options include chemoimmunotherapy. 23 „„ For next-in-line treatment, ibrutinib, venetoclax with rituximab, duvelisib, and idelalisib with rituximab are preferred. 24 Richter’s transformation „„ For a few people, CLL changes into a faster-growing cancer. It may change into DLBCL ( d iffuse l arge B - c ell l ymphoma) or Hodgkin lymphoma. In general, clinical trials and treatment for the specific cancer are options. 26 Is supportive care needed? People with CLL are likely to get infections and other illnesses. Supportive care includes treatment for the health problems caused by CLL and cancer treatment. 26 How can you decide between options? „„ Don’t be shy and ask your doctors questions. They are there to help. „„ Get a second opinion. Even doctors get second opinions. „„ Support groups can be helpful. You can learn a lot from others. „„ Compare the pros and cons of each option. 30 NCCN Guidelines for Patients ® Page Number Ü NCCN.org/patients - for Patients | NCCN.org - for Clinicians The NCCN QUICK GUIDE tm series and NCCN Guidelines for Patients ® are supported by charitable donations made to the NCCN Foundation ® . For more details and the full library of patient and caregiver resources, visit NCCN.org/patients. DONATE NOW NCCNFoundation.org/Donate

RkJQdWJsaXNoZXIy NjUyNTk0